Simpler Grants.gov #HT942526PCARPFPTA

Army and DHA Seek Proposals for Pancreatic Cancer Research Program Focused Pilot Award

The Department of the Army, through the U.S. Army Medical Research Acquisition Activity (USAMRAA) and the Defense Health Agency's Congressionally Directed Medical Research Programs (CDMRP), is seeking proposals for the FY26 Pancreatic Cancer Research Program (PCARP) Focused Pilot Award. - Government Buyer: - Department of the Army, U.S. Army Medical Research Acquisition Activity (USAMRAA) - Defense Health Agency, Research and Development (DHA R&D) - Congressionally Directed Medical Research Programs (CDMRP) - Products/Services Requested: - Focused Pilot Award for innovative, patient-centered pancreatic cancer research - Emphasis on supportive care, quality of life, and survivorship - Supports clinical research studies only (excludes clinical trials and preclinical animal studies) - Up to four awards anticipated, each with a maximum value of $300,000 - Total available funding is approximately $1.2 million - Unique/Notable Requirements: - Open to both extramural and intramural applicants, including U.S. Department of War organizations - Research must be innovative and patient-centered - Clinical trials and preclinical animal studies are specifically excluded - No specific OEMs or commercial vendors are named, as this is a research grant opportunity rather than a procurement of products or commercial services.

Description

The fiscal year 2026 (FY26) Pancreatic Cancer Research Program (PCARP) Focused Pilot Award supports the exploration and development of impactful and innovative concepts under a patient-centered focus area of pancreatic cancer research that could ultimately lead to major advancements that will have a profound effect on patients' overall quality of life. The research this award supports should strive to produce robust preliminary data that can serve as a foundation for future clinical or real-world research application. This award mechanism allows, but does not require, preliminary data and supports clinical research studies but does not allow clinical trials or preclinical animal studies. The program expects to fund approximately four awards with a total funding of roughly $1.2 million and a maximum period of performance of 2 years.

View original listing